Arcus Biosciences (RCUS) News Today $15.50 +0.04 (+0.26%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past weekDecember 20 at 10:27 PM | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Jane Street Group LLCJane Street Group LLC grew its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 59.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 217,041 shares of the company's stock after acquiring an additional 8December 20 at 3:56 AM | marketbeat.comState Street Corp Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS)State Street Corp decreased its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 1.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,011,174 shares of the company's stock after selling 43,882 shares during thDecember 20 at 3:39 AM | marketbeat.comArcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 19 at 4:05 PM | businesswire.comPrecision gains CTA approval in Hong Kong for chronic hepatitis B therapy trialDecember 19 at 12:22 PM | msn.comCharles Schwab Investment Management Inc. Purchases 59,536 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Charles Schwab Investment Management Inc. raised its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 11.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 566,979 shares of the company's stock after acquiring an additionDecember 11, 2024 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsDecember 10, 2024 | businesswire.comFmr LLC Buys 286,766 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Fmr LLC boosted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 6.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,467,557 shares of the company's stock after acquiring an addDecember 7, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $37.26 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)Point72 Asset Management L.P. lifted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 32.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,437,073 shares of the company's stock after buying an additionalDecember 6, 2024 | marketbeat.comParkman Healthcare Partners LLC Acquires 610,219 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Parkman Healthcare Partners LLC raised its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 146.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,025,754 shares of the company's stock afDecember 4, 2024 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsDecember 3, 2024 | businesswire.comWalleye Capital LLC Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS)Walleye Capital LLC acquired a new position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 238,544 shares of the company's stock, valued at approximately $3,647,000. WalleyeDecember 3, 2024 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Buy" by BrokeragesShares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have received an average rating of "Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued aDecember 2, 2024 | marketbeat.comSuvretta Capital Management LLC Cuts Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)Suvretta Capital Management LLC cut its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 30.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 663,603 shares of the company's stock aftNovember 29, 2024 | marketbeat.comAlgert Global LLC Purchases 36,590 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Algert Global LLC raised its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 48.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 112,847 shares of the company's stoNovember 28, 2024 | marketbeat.comCautious Outlook on Arcus Biosciences Amid Uncertain TIGIT-Based TreatmentsNovember 27, 2024 | markets.businessinsider.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Buys 186,750 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 25.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 931,048 shares of the compaNovember 24, 2024 | marketbeat.comArcus Biosciences to Participate in Two Upcoming Investor ConferencesNovember 19, 2024 | businesswire.comBuy Rating for Precision BioSciences Driven by Promising Gene Editing Advancements in cHBV TherapyNovember 19, 2024 | markets.businessinsider.comArcus Biosciences Announces New Employment Inducement GrantsNovember 12, 2024 | businesswire.comGSA Capital Partners LLP Has $2.87 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)GSA Capital Partners LLP boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 17.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,415 shares of the company's stock after purchasing an additional 28,307 shares duringNovember 12, 2024 | marketbeat.comEquities Analysts Offer Predictions for RCUS FY2024 EarningsArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst E. Bodnar now forecasts that the cNovember 11, 2024 | marketbeat.comAnalysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter ReportNovember 9, 2024 | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comArcus Biosciences Reports Q3 2024 ResultsNovember 7, 2024 | markets.businessinsider.comHold Rating for Arcus Biosciences Amid Uncertainty and Competitive ChallengesNovember 7, 2024 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for Arcus Biosciences (RCUS)November 7, 2024 | markets.businessinsider.comArcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...November 7, 2024 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPSArcus Biosciences (NYSE:RCUS - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.07. The business had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 100.81% and a negative return on equity of 42.86%. The company's quarterly revenue was up 50.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.94) EPS.November 7, 2024 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Buy" from AnalystsArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned a consensus rating of "Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given aNovember 7, 2024 | marketbeat.comArcus Biosciences, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 6, 2024 | seekingalpha.comArcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline UpdateNovember 6, 2024 | businesswire.comExpert Outlook: Arcus Biosciences Through The Eyes Of 8 AnalystsNovember 6, 2024 | benzinga.comArcus Biosciences (NYSE:RCUS) Given Neutral Rating at HC WainwrightHC Wainwright reiterated a "neutral" rating and issued a $20.00 target price on shares of Arcus Biosciences in a report on Wednesday.November 6, 2024 | marketbeat.comWhat To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 EarningsNovember 6, 2024 | uk.finance.yahoo.comArcus Biosciences announces results from Part 1 of ARC-10 trialNovember 6, 2024 | markets.businessinsider.comArcus Biosciences Says Domvanalimab Plus Zimberelimab Improved Overall Survival In ARC-10November 6, 2024 | markets.businessinsider.comArcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual MeetingOctober 30, 2024 | finance.yahoo.comArcus Biosciences (RCUS) Set to Announce Earnings on WednesdayArcus Biosciences (NYSE:RCUS) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638380)October 30, 2024 | marketbeat.comArcus Biosciences: Advancing On Several FrontsOctober 29, 2024 | seekingalpha.comArcus Biosciences’ Casdatifan Shows Promising Efficacy and Safety in Phase 1 Trial, Supporting Buy RatingOctober 25, 2024 | markets.businessinsider.comArcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Should You Sell?Arcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Here's WhyOctober 25, 2024 | marketbeat.comPrecision BioSciences to Report Q3 Earnings: What's in the Cards?October 25, 2024 | uk.finance.yahoo.comArcus Biosciences price target raised to $29 from $25 at BarclaysOctober 25, 2024 | markets.businessinsider.comArcus Biosciences: Neutral Rating Amid Early-Stage Data Uncertainties and Competitive Market ChallengesOctober 25, 2024 | markets.businessinsider.comArcus Biosciences Announces New Employment Inducement GrantsOctober 24, 2024 | businesswire.comArcus Biosciences (NYSE:RCUS) Sees Large Volume Increase - Should You Buy?Arcus Biosciences (NYSE:RCUS) Sees Strong Trading Volume - What's Next?October 24, 2024 | marketbeat.comArcus Biosciences Shares Rise After Kidney Cancer Drug Shows Promise in Early-Stage TrialOctober 24, 2024 | marketwatch.comFirst Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney CancerOctober 24, 2024 | businesswire.comArcus Biosciences initiated with a Neutral at H.C. WainwrightOctober 23, 2024 | markets.businessinsider.com Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. RCUS Media Mentions By Week RCUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCUS News Sentiment▼0.780.60▲Average Medical News Sentiment RCUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCUS Articles This Week▼55▲RCUS Articles Average Week Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cytokinetics News Today Viking Therapeutics News Today TG Therapeutics News Today BridgeBio Pharma News Today Crinetics Pharmaceuticals News Today Krystal Biotech News Today Arcellx News Today ADMA Biologics News Today Apellis Pharmaceuticals News Today Ultragenyx Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RCUS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts